Accuracy of recall of histories of oral contraceptive use

Glass, Roger I.; Johnson, Bridget; Vessey, Martin

doi:10.1136/jech.28.4.273

Cited by 29 publications

(16 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…records for HT use 42 as well as other reproductive factors. 43,44 Our results may be due to chance as these interactions do not survive correction for multiple hypothesis testing, but the fact that these are confirmed susceptibility alleles adds support to our findings. Given the role of estrogen in TERT activation and expression, rs10069690 is of particular interest.…”

Section: Discussionsupporting

confidence: 62%

A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer

Lee

Bomkamp

Bandera

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

Menopausal estrogen-alone therapy (ET) is a well-established risk factor for serous and endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, which is partly attributable to 18 confirmed ovarian cancer susceptibility loci identified by genome-wide association studies. The interplay among these loci, ET use and ovarian cancer risk has yet to be evaluated. We analyzed data from 1,414 serous cases, 337 endometrioid cases and 4,051 controls across 10 case–control studies participating in the Ovarian Cancer Association Consortium (OCAC). Conditional logistic regression was used to determine the association between the confirmed susceptibility variants and risk of serous and endometrioid ovarian cancer among ET users and non-users separately and to test for statistical interaction. A splicing variant in TERT, rs10069690, showed a statistically significant interaction with ET use for risk of serous ovarian cancer (pint = 0.013). ET users carrying the T allele had a 51% increased risk of disease (OR = 1.51, 95% CI 1.19–1.91), which was stronger for long-term ET users of 10+ years (OR = 1.85, 95% CI 1.28–2.66, pint = 0.034). Non-users showed essentially no association (OR = 1.08, 95% CI 0.96–1.21). Two additional genomic regions harboring rs7207826 (C allele) and rs56318008 (T allele) also had significant interactions with ET use for the endometrioid histotype (pint = 0.021 and pint = 0.037, respectively). Hence, three confirmed susceptibility variants were identified whose associations with ovarian cancer risk are modified by ET exposure; follow-up is warranted given that these interactions are not adjusted for multiple comparisons. These findings, if validated, may elucidate the mechanism of action of these loci.

show abstract

Section: Discussionsupporting

confidence: 62%

A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer

Lee

Bomkamp

Bandera

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…A number of large, carefully conducted studies (26-29) have failed to reproduce these conclusions including the Cancer and Steroid Hormone Study (CASH) (26) which carries particular authority by reason of its size and scope. Analysis of the CASH data on 689 cases and 1077 controls suggested no modification of risk even in women with more than 11 years of use beginning 15 years earlier (RR=0.8), in those with prior benign breast disease or with prolonged oral contraceptive use before first pregnancy. Similar reassurance is provided by the data of Vessey er al., (27) based on 1176 case-control pairs.…”

Section: Oral Contraceptives and Breast Cancermentioning

confidence: 97%

Therapeutic Progress—review Xvii: Oral Contraception and Cancer of the Female Reproductive System

Woods

1985

J Clin Pharm Ther

View full text Add to dashboard Cite

“…However, random error in exposure data, if present, would lead to a dilution of any observed effect and would not have an important effect on the results. Several studies have shown good agreement between questionnaire data and physicians' records of basic data on OCP use (15)(16)(17). The questions on pregnancy had been validated by personal interview in a previous study (14).…”

Section: Discussionmentioning

confidence: 99%

The pill, parity, and rheumatoid arthritis

Spector

Roman

Silman

1990

Arthritis & Rheumatism

136

View full text Add to dashboard Cite

We report on a case-control study investigating the relationship of oral contraceptive pill (OCP) use and parity to the development of rheumatoid arthritis (RA). Women with RA were compared with 2 separate control groups, women with osteoarthritis (OA) and women randomly selected from a population-based electoral register. Nulliparity was found to be a risk factor for the development of RA, with age-adjusted odds ratios of 1.82 (95% confidence interval [CI] 1.09-3.03) versus the OA control group and 1.83 (95% CI 1.03-3.06) versus the population control group. Use of OCPs before the age of 35 was negatively associated with RA (odds ratio 0.56, 95% CI 0.29-1.12 versus the OA control group; odds ratio 0.6, 95% CI 0.30-1.17 versus the population control group). Some evidence of a duration-response effect was seen, although the numbers were small. The 2 variables were also multiplicative, with nulliparous non-OCP users having a 4-fold risk of RA compared with parous OCP users. These findings suggest that pregnancy and OCP use have a "protective effect" on the development of RA, although the mechanism remains unclear.-. Epidemiologic and immunologic evidence suggests that hormonal factors may play a role in the etiology and course of rheumatoid arthritis (RA). This hypothesis is based on several observations, including a 2-3-fold excess incidence in women at all ages ( l ) , an amelioration of the disease in 80% of women during pregnancy (2). and reported variations in disease severity during the menstrual cycle (3). It has also been suggested that pregnancy may play a role in the later development of RA. However, the evidence about the direction of this association is contradictory. One large population study indicated that parous women are more likely to develop R A (4). whereas another indicated that nulliparous women are at increased risk ( 5 ) . From theA number of European studies have indicated that women who have used the oral contraceptive pill (OCP) are less likely to develop RA than women who have not used it (6-9). Studics from the United States, however, have failed to show a similar relationship (10.1 1). The reasons for these discrepancies are unclear, but differences in study design, patient selection, and methods of analysis have been implicated (12).We report herein the findings of an investigation into the effects of panty and OCP use on the development of RA. PATIENTS AND METHODSPatients. The study had a case-control design. Two hundred ninety female outpatients (age range 35-70 years) who attended 1 of 6 rheumatology centers in east London were studied. The diagnosis of RA was made by the attending physician, according to the criteria of the American Rheumatism Association (13). The majority of the patients (89%) had used a second-line agent at some time, and 76% were seropositive. Women <35 years old were excluded

show abstract

Accuracy of recall of histories of oral contraceptive use

Cited by 29 publications

References 2 publications

A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer

A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer

Therapeutic Progress—review Xvii: Oral Contraception and Cancer of the Female Reproductive System

The pill, parity, and rheumatoid arthritis

Contact Info

Product

Resources

About